Tyrosine hydroxylase-positive dopaminergic neuron (TH+ DA neuron)

Tyrosine hydroxylase-positive (TH+) dopaminergic neurons are a specialized neuronal population characterized by the expression of tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis (Nagatsu et al., 1964 [1]). These neurons are primarily clustered in the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA) of the midbrain, where they play pivotal roles in motor coordination, reward processing, and executive function (Björklund & Dunnett, 2007 [2]). The selective degeneration of TH+ neurons in the SNc is the hallmark of Parkinson's disease, leading to the classic motor symptoms of tremor, rigidity, and bradykinesia (Dauer & Przedborski, 2003 [3]). In contrast, overactivity or dysregulation of dopaminergic pathways originating in the VTA is associated with psychiatric conditions such as schizophrenia and substance use disorders (Wise & Jordan, 2021 [4]). Therapeutic interventions targeting these neurons often involve dopamine replacement therapy (e.g., Levodopa), dopamine receptor agonists, or inhibitors of dopamine degradation to compensate for neuronal loss or modulate signaling (StatPearls, 2023 [5]). Emerging therapies also explore neuroprotective agents and cell replacement strategies to restore the TH+ neuronal population (Barker et al., 2018 [6]).

Other names

TH-positive neuronsDopaminergic neuronsDA neuronsMidbrain dopaminergic neuronsTyrosine hydroxylase-expressing neurons

Dopamine precursor supplementation, dopamine receptor agonism, inhibition of dopamine metabolism (MAO-B and COMT inhibition), and enhancement of dopamine release [3, 5].